PIII arrives at its May 14 earnings release riding one of the sharper short-term price moves among its health-care peers — up 49% in a month, 33% in a week, and 6.5% on Monday alone.
The rally has come with remarkably low short-selling pressure. Short interest is just under 2% of the float — a level that barely registers as a bearish signal. It has also been falling sharply: down nearly 29% over the past month as short sellers covered into rising prices. Borrow costs are modest at 7.4%, and availability in the lending market remains loose, sitting well below the 52-week high in utilisation. The ORTEX short score of 44.5 is mid-range — not a red flag in either direction. Nothing in the short-selling data suggests organised bearish conviction ahead of the print.
The debate around PIII is less about shorts and more about whether the recent price move can find fundamental support. The business carries real weight: estimated revenue near $1.54 billion, but with a net loss of roughly $74 million and net debt of $93.7 million. Operating cash flow is positive at around $28 million — a meaningful anchor for a company at this scale — but the gap between revenue and profitability remains wide. On the analyst side, the only recent coverage on record saw TD Cowen cut its target from $8 to $3 in April and Lake Street trim to $4 from $12.50 in late March, both maintaining their ratings. The mean analyst target of $3.50 is actually below Monday's close of $3.78, suggesting the Street's existing marks have already been overtaken by the move. Analyst data beyond those two actions is stale and should be treated with caution.
Ownership is highly concentrated. Chicago Pacific Founders holds approximately 42.7% of shares, and Leavitt Equity Partners controls another 10.8%. Together, those two investors account for the majority of the float — which means price discovery is thin and individual session moves can look dramatic on light volume. The RSI-14 is at 69, close to overbought territory, after a stock that was trading under $1 as recently as mid-2024.
The May 14 print therefore becomes a test of whether the business can show a credible path to narrowing losses — and whether cash generation can hold — at a moment when the stock has well outrun the targets of its few remaining sell-side followers.
See the live data behind this article on ORTEX.
Open PIII on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
